Hematopoietic & Lymphoid System White Cell disorders

Ghadeer Hayel, M.D. Assistant professor of Pathology Mutah University Consultant hematopathologist 3/26/2025

Reactive Lymphadenitis

2



- The most important disorders of white cells are neoplasms.
- Virtually all are considered to be malignant, but have a wide range of behaviors, ranging from the most aggressive cancers of man to indolent.
- As a group they are quite common.
- Occur at all ages , some preferentially affect infants, children, young adults, & the very old.
- In our discussion we'll divide them into three broad categories based on the **cell of origin** & differentiation of tumor cells:
- 1) Lymphoid neoplasms.
- 2) Myeloid neoplasms.
- 3) Histiocytic neoplasms

2. Neoplastic Proliferations of White Cells

Lymphoid Neoplasms

They can manifest as:

- Leukemias: involvement of the bone marrow (BM) & the peripheral blood (PB) (usually, not always)
- Lymphomas: tumors that produce masses in lymph nodes or other tissues.
- ✓ Other (plasma cell neoplasm)
- ✓ All can spread to lymph nodes & other tissues (<u>liver</u>, <u>spleen</u>, <u>bone marrow</u>, <u>and peripheral blood</u>)

- B and T cell tumors are composed of cells that are arrested at or derived from a specific stage of normal lymphocyte differentiation
- ▷ Diagnosis & classification → rely on tests (immunohistochemistry or flow cytometry) that detect lineage-specific antigens (e.g., B cell, T cell, & NK cell markers) and markers of maturity.
- Many such markers are identified by their cluster of differentiation (CD) number. (e.g., CD8, CD4, or CD20).



8

- Cluster of differentiation antigin (CD): commonly used as cell markers in immunophenotyping, allowing cells to be defined based on what molecules are present on their surface.
- 1) B-cell markers: CD19, CD79, and CD20
- 2) T-cell markers: CD3 (either CD4 or CD8)
- TdT: a marker of early lymphoid origin (B & T lymphoblasts)



9

- ✓ Upon antigen stimulation → B cells enter germinal centers
 → undergoes Class switching and Somatic hypermutation (Goal is: antibody Diversification)
- ✓ This is a <u>mistake-prone</u> forms of regulated genomic instability that place germinal center B cells at relatively high risk for potentially transforming mutations. (genetic errors that occur during antigen receptor gene rearrangement and diversification) → most of B-cell lymphomas.

- Lymphoid neoplasms and immune system function.
- Can cause Immunodeficiency (↑ susceptibility to infection).
- 2) Can cause Autoimmunity
- 3) Inherited or acquired immune deficiencies ↑ the risk for the development of certain lymphomas (usually EBV associated)

11

- So they are either B or T cell neoplasms.
- Two groups of lymphomas are recognized : Hodgkin lymphomas (HD) & non-Hodgkin lymphomas (NHL)
- The World Health Organization (WHO) has formulated a widely accepted classification scheme, relies on a combination of morphologic, phenotypic, genotypic, and clinical features.

Precursor B Cell Neoplasms

Precursor B cell leukemia/lymphoma (B-ALL)

Peripheral B Cell Neoplasms

B cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) B cell prolymphocytic leukemia Lymphoplasmacytic lymphoma Mantle cell lymphoma Follicular lymphoma Extranodal marginal zone lymphoma Splenic and nodal marginal zone lymphoma Hairy cell leukemia Plasmacytoma/plasma cell myeloma Diffuse large B cell lymphoma (multiple subtypes) Burkitt lymphoma

Precursor T Cell Neoplasms

Precursor T cell leukemia/lymphoma (T-ALL)

Peripheral T/NK Cell Neoplasms

T cell prolymphocytic leukemia T cell granular lymphocytic leukemia Mycosis fungoides/Sézary syndrome Peripheral T cell lymphoma, unspecified Angioimmunoblastic T cell lymphoma Anaplastic large cell lymphoma Enteropathy-type T cell lymphoma Panniculitis-like T cell lymphoma Hepatosplenic $\gamma\delta$ T cell lymphoma Adult T cell lymphoma/leukemia Extranodal NK/T cell lymphoma Aggressive NK cell leukemia

Hodgkin Lymphoma

Nodular sclerosis Mixed cellularity Lymphocyte-rich Lymphocyte-depleted Lymphocyte predominant

Acute Lymphoblastic Leukemia/Lymphoma (ALL)

- Neoplasms composed of immature B (pre-B) or T (pre-T)
 cells -> called Lymphoblasts.
- 85% B-cells, commonly manifest as acute LEUKEMIA
 The most common cancer of children (Peak : 3 years)
 15% T-cells, commonly manifest as thymic LYMPHOMA
- Peak: adolescence

Acute Lymphoblastic Leukemia/Lymphoma (ALL) : Genetics

Pre-B cell

- Hyperdiploidy (> 50chromosomes/cell)
- ▶ t(12;21).
- t(9;22) involving ABL & BCR genes.

Pre-T cell

- NOTCH1 mutations
- CDKN2A mutations



Acute Lymphoblastic ¹⁵ Leukemia/Lymphoma (ALL) : Morphology

- ▶ Leukemia : the marrow is hypercellular & packed with lymphoblasts → replace normal marrow elements.
- Lymphoma : Mediastinal (thymic) mass & is more likely to involve lymph nodes & spleen.
- Blasts: scant basophilic cytoplasm and nuclei with <u>delicate, finely stippled chromatin</u> & small nucleoli.
- In pre-B & pre-T ALLs the blasts are identical in routine stains (immunophenotype is needed)

Acute Lymphoblastic 16 Leukemia/Lymphoma (ALL) : Morphology



17

Normal <u>mature</u> lymphocyte

Normal bone marrow



Acute Lymphoblastic

18 Leukemia/Lymphoma (ALL) : Clinical features

Presentation:

- 1) Symptoms related to depression of marrow function; anemia, neutropenia & bleeding.
- 2) Mass effects \rightarrow neoplastic infiltration; bone pain
- 3) CNS manifestations headache, vomiting, and nerve palsies.
- Aggressive but curable (85% cure rate in children), but remains the leading cause of cancer deaths in children

Acute Lymphoblastic Leukemia/Lymphoma (ALL) : Clinical features

Worse prognosis

19

- Younger than 2
- Older than 10
- PB WBC count > 100,000
- ▶ t(9;22)

Favorable prognosis

Age between 2-10

 $(\begin{tabular}{c} \begin{tabular}{c} \end{tabular}$

~

- PB Low WBC count
- Hyperdiploidy
- ▶ t(12;21)

²⁰ Chronic Lymphocytic Leukemia/Small ²⁰ Lymphocytic Lymphoma (CLL/SLL)

- An indolent, slowly growing tumor (increased tumor cell survival is more important than tumor proliferation)
- CLL & SLL are essentially identical.
- ▶ CLL \rightarrow If PB involvement count exceeds 5000 cells/µL
- The most common leukemia of adults in the West.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) : Morphology

- Involved lymph nodes are effaced by:
- 1) Sheets of small lymphocytes with dark, round nuclei, **clumped** chromatin & scanty cytoplasm.
- 2) Small percentage of large lymphocytes with prominent centrally located nucleoli \rightarrow prolymphocytes.

Chronic Lymphocytic Leukemia/SmallLymphocytic Lymphoma (CLL/SLL) : Morphology

Green arrow: cells w Clumped chromatin & white areas in between conferring a "soccer ball" appearance. Yellow arrow : prolymphocytes



Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) : Immunophenotype

23

- ▶ A neoplasm of mature B cells → expressing the CD20.
- The tumor cells also express CD5 (diagnostic clue, only SLL & MCL express it)

24 Chronic Lymphocytic Leukemia/Small 24 Lymaphocytic Lymphoma (CLL/SLL) : Clinical features

- Old age. Often asyptomatic. But symptoms are nonspecific; easy fatigability, weight loss, anorexia, generalized lymphadenopathy & hepatosplenomegaly.
- Peripheral lymphocytosis (>5000)
- Indolent disease but cure may only be achieved with hematopoietic stem cell transplantation (HSCT)
- 10-15% develop autoimmune hemolytic anemia & thrombocytopenia.

25 Follicular Lymphoma

- ▶ Relatively common tumor \rightarrow 40% of the adult NHLs
- ▶ Pathogenesis: a characteristic (14;18) translocation that fuses the BCL2 gene on chromosome 18 to the IgH locus on chromosome 14 → inappropriate "overexpression" of BCL2 protein (an inhibitor of apoptosis) → contributes to cell survival)

Follicular Lymphoma – Morphology

- Lymph nodes usually are effaced by a distinctly nodular (follicular) proliferation
- Two types of neoplastic cells,
- 1) the <u>predominant</u> called centrocytes have <u>angular</u> "cleaved" & indistinct nucleoli,
- 2) the other centroblasts, <u>larger</u> cells with vesicular chromatin, <u>several nucleoli</u>.

Follicular Lymphoma – Morphology

Centrocyte centroblast



Follicular Lymphoma – Immunophenotype

- B-cells markers (mature B cell neoplasm).
- ▷ CD10 → GC marker (expressed in Burkitt lymphoma, B-ALL & some DLBCL)

29 Follicular Lymphoma - Clinical features

- Older than 50
- Generalized painless lymphadenopathy
- Bone marrow is involved in 80% of cases
- Prolonged survival, not curable disease (indolent)
- ▶ 40% transform into DLBCL, **dismal** prognosis

Mantle Cell Lymphoma

 composed of cells resembling the naive B cells found in the mantle zones of normal lymphoid follicles.

30

mainly in men older than 50 years of age



31 Mantle Cell Lymphoma – Pathogenesis & immuno.

- ► All tumors have an (11;14) translocation → fuses the cyclin D1 gene to the IgH locus → overexpression of cyclin D1→ stimulates growth by promoting the progression of cell cycle from G1 to S phases)
- Immunophenotype:
- 1) B cell markers.
- 2) CD5 (as CLL/SLL)
- 3) Cyclin D1 (not expressed in CLL/SLL)

32 Mantle Cell Lymphoma – Morphology

- A diffuse involvement of the lymph node.
- The tumor cells are slightly larger than normal lymphocytes with irregular nucleus, inconspicuous (not clear) nucleoli.
- Bone marrow is involved in most cases.
- sometimes arises in the GIT as multifocal polyps (lymphomatoid polyposis).

33 Mantle Cell Lymphoma – Clinical features

- Patients Present with fatigue & lymphadenopathy found to have generalized disease involving the bone marrow, spleen, liver, and (often) GIT.
- Moderately aggressive & incurable.
- The median survival is 4-6

THANK YOU!